Collaboration will develop phenotypic personalized medicine platform for cancer patients

June 27, 2016
IntelliCyt and Notable Labs will further the development of a predictive personalized medicine platform for cancer patients.

IntelliCyt (Albuquerque, NM), which develops integrated platforms that accelerate drug discovery, antibody discovery, and immuno-oncology research, is collaborating with Notable Labs (San Francisco, CA) to further the development of a predictive personalized medicine platform. The two companies recognize that next-generation platforms must integrate immune profiling in physiologically relevant ex vivo microenvironments (cancer patient cells, in this case) to ensure clinical translation of laboratory results.

Related: Fluorescing engineered DNA promises personalized cancer therapy

Notable Labs helps oncologists identify effective therapies that they can prescribe by testing them on a patient's own cells. This approach promises tailored treatment options fast enough for doctors to put to use. By testing a broad set of drugs and drug combinations, the company is able to functionally profile cancer cells, which leads to a better understanding of the biological mechanisms of the patient's cancer. Providing this information to physicians can improve treatment outcomes while reducing side effects.

Notable Labs will use IntelliCyt's iQue Screener PLUS platform in a fully automated, high-throughput laboratory to immune-profile phenotypic and functional endpoints of cells and secreted proteins through cell- and bead-based assays. Prioritized treatment options will be highlighted in reports to clinicians using Notable Lab's screening process with IntelliCyt's immune-profiling technology.

The platform, which integrates an instrument, software and reagent system, offers a proprietary high-throughput sampling capability that enables the rapid assessment of cells and beads in suspension in 96-, 384-, and 1536-well plates. Miniaturization of the assay is possible to save reagent cost and conserve samples, and high-content, multiplex readouts are generated on each individual cell or bead via the flow cytometry-based detection system.

For more information, please visit www.intellicyt.com and www.notablelabs.com.

Sponsored Recommendations

March 31, 2025
Enhance your remote sensing capabilities with Chroma's precision-engineered optical filters, designed for applications such as environmental monitoring, geospatial mapping, and...
March 31, 2025
Designed for compatibility with a wide range of systems, Chroma's UV filters are engineered to feature high transmission, superior out-of-band blocking, steep edge transitions...
March 31, 2025
Discover strategies to balance component performance and system design, reducing development time and costs while maximizing efficiency.
March 31, 2025
Filter accessories including cubes, sliders, and rings, designed to enhance the performance and versatility of optical systems. These components ensure precise alignment and stability...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!